Multivariate analysis for OS from CR
| . | All patients . | t(8;21) . | inv(16)/t(16;16) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Log(WBC)* | 1.06 | 0.39-2.89 | .91 | 1.57 | 0.35-7.13 | 0.56 | 0.84 | 0.23-3.17 | .80 |
| RTK gene mutation | 1.73 | 0.70-4.30 | .24 | 1.34 | 0.41-4.44 | 0.63 | 2.21 | 0.50-9.78 | .30 |
| MRD2 reduction ≥ 3 logs | 0.51 | 0.20-1.31 | .16 | 0.31 | 0.09-1.03 | 0.056 | 0.92 | 0.21-4.13 | .91 |
| . | All patients . | t(8;21) . | inv(16)/t(16;16) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | |
| Log(WBC)* | 1.06 | 0.39-2.89 | .91 | 1.57 | 0.35-7.13 | 0.56 | 0.84 | 0.23-3.17 | .80 |
| RTK gene mutation | 1.73 | 0.70-4.30 | .24 | 1.34 | 0.41-4.44 | 0.63 | 2.21 | 0.50-9.78 | .30 |
| MRD2 reduction ≥ 3 logs | 0.51 | 0.20-1.31 | .16 | 0.31 | 0.09-1.03 | 0.056 | 0.92 | 0.21-4.13 | .91 |
Comparisons were based on cause-specific hazard Cox models, stratified on treatment arm and CBF subset when applicable, and the 12 patients who received allogeneic SCT in first hematological CR were censored at SCT time.
RTK, receptor tyrosine kinase (KIT and/or FLT3).
Tested as continuous variable.